Thermo Fisher Bets on Augmented and Virtual Reality

News
Article

The company’s new training center in Greenville, NC, will use virtual and augmented reality to train employees on its sterile injectables manufacturing line, which is expected to cut training time in half.

On Aug. 19, 2019, Thermo Fisher Scientific dedicated its new employee training center in Greenville NC. The center features virtual and augmented reality (VR and AR) capabilities, which simulate real-world equipment and the plant floor environment, bringing trainees closer to the experience of running the equipment than they would be in many traditional training programs. The company expects use of VR and AR to cut training time by 50%, according to a press release issued on August 13, 2019.

Training for work on a sterile injectable manufacturing line typically requires more than one year, but with VR and AR, Thermo Fisher’s managers say, employees can gain the necessary skills in roughly four months and better retain more of what they learn during training. Especially important is the fact that VR and AR give trainees the ability to “walk through” the steps needed to perform their jobs before beginning real work on the manufacturing line.

The Greenville Training Center will feature five VR rooms and will allow 20 people to be trained at a time.

Thermo Fisher Scientific plans to add more VR and AR training modules in the future that will be focused on pre-filled syringes, continuous manufacturing, and other topics.

Source: Thermo Fisher Scientific 

 

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content